[The first rotavirus vaccine approved in the USA and Europe].
A new live oral rotavirus vaccine (Rotashield) has now been approved both in the USA and Europe. In large multicentre trials involving over 10,000 children, the vaccine has been shown to have a manifest protective effect, first and foremost against severe rotavirus-induced diarrhoea, but to be associated with certain side effects. The Advisory Committee on Immunisation Practices and the American Academy of Paediatrics are now recommending that Rotashield be included in the child vaccination programme. Use of the vaccine in Europe is likely to vary from one country to another. The issue of general recommendations for its use in Sweden should await the results of cost-benefit analysis and review of experience of the vaccine's use in the USA. In addition, a more comprehensive identification of rotavirus serotypes occurring in Sweden is a prerequisite for adequate assessment of the vaccine's necessity in this country.
Svensson
L
L
Smittskyddsinstitutet, Solna.
Johansen
K
K
Uhnoo
I
I
D003968:Diarrhea, Infantile / Q000517:prevention & control / Q000821:virology; D005060:Europe; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D012400:Rotavirus Infections / Q000517:prevention & control* / Q000821:virology; D014481:United States; D014765:Viral Vaccines / Q000008:administration & dosage / Q000600:supply & distribution*
D014765:Viral Vaccines
Första rotavirusvaccinet godkänt i USA och Europa.